| 3 min read
From vein-to-vein tracking to the plasmid bottleneck, logistics are the new efficacy endpoint
| 4 min read
Why the "make or buy" decision is no longer just about cost, but about the survival of the therapy itself
| 4 min read
How simulating the future is helping the industry abandon the "black box" of bioreactor biologyArticles
| 4 min read
How the industry is pivoting from "grams to tons" to meet the demand for population-level RNA therapeutics
| 3 min read
How targeted protein degradation is rewriting the rules of pharmacology and drugging the "undruggable"
| 4 min read
Why the "maximum tolerated dose" is obsolete for drugs that act like code
| 4 min read
From high-dose toxicity to commercial withdrawal, the path to a cure is paved with cautionary tales
| 3 min read
As the modality matures, safety signals and manufacturing hurdles force a regulatory rethink
| 4 min read
Why the "build it and they will come" model fails in rare disease, and how AI and concierge care are bridging the gap
| 4 min read
Why the "one-drug, one-target" biomarker model is obsolete in the age of living therapies
| 4 min read
As modalities shift from inert chemicals to biologically active gene therapies, developers must decide: rely on the broad sweep of standard histopathology or invest in the granular precision of mechanistic profiling.
| 4 min read
The "gold standard" has a blind spot: finding truth in the noise of clinical practice
